Cullinan Therapeutics Inc. (CGEM), a clinical-stage biopharmaceutical company, is scheduled to host an Immunology Day tomorrow, i.e., June 10, 2026. The event will include updates on CLN-978 and Velinotamig, along with related clinical and development progress.
CLN-978 is a potent CD19xCD3 bispecific T cell engager designed to help the immune system target and kill B cells that express CD19. It works by directing T cells to recognize and destroy these cells both in lab and living systems. It is engineered to bind very strongly to CD19, allowing it to effectively target even B cells with low levels of CD19.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.